Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)FRA:E0C -2.19%79 PS Ratio is 4.34 as of Jul. 27, 2026, which is 23% below its 10-year median of 5.65. GuruFocus rates FRA:E0C with a GF Score™ of 79/100 and a GF Value™ of €2.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 658 Healthcare Providers & Services companies, Carasent AB (publ) ranks worse than 79.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Carasent AB (publ)'s share price is €2.055.
Carasent AB (publ)'s Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.47. Hence, Carasent AB (publ)'s PS Ratio for today is 4.34.
Good Sign:
Carasent AB (publ) stock PS Ratio (=4.62) is close to 2-year low of 4.45.
The historical rank and industry rank for Carasent AB (publ)'s PS Ratio or its related term are showing as below:
FRA:E0C'
s PS Ratio Range Over the Past 10 Years
Min: 0.54 Med: 5.65 Max: 35.4
Current: 4.62
During the past 13 years, Carasent AB (publ)'s highest PS Ratio was 35.40. The lowest was 0.54. And the median was 5.65.
FRA:E0C's PS Ratio is ranked worse than 79.79% of 658
companies
in the Healthcare Providers & Services industry
Industry Median: 1.465
vs FRA:E0C: 4.62
During the past 12 months, the average Revenue per Share Growth Rate of Carasent AB (publ) was 16.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 23.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 25.40% per year.
During the past 13 years, Carasent AB (publ)'s highest 3-Year average Revenue per Share Growth Rate was 109.00% per year. The lowest was -65.00% per year. And the median was 22.00% per year.
Back to Basics: PS Ratio
Carasent AB (publ) (FRA:E0C) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Carasent AB (publ) PS Ratio Related Terms
Carasent AB (publ) PS Ratio Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Carasent AB (publ)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s PS Ratio distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Carasent AB (publ)'s Share Price of today is €2.055. Carasent AB (publ)'s Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Carasent AB (publ) (FRA:E0C) has a PS Ratio of 4.34 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Carasent AB (publ) and its competitors. This is 23% below median its historical median of 5.65. Over the past decade, Carasent AB (publ)'s PS Ratio has ranged from 0.54 to 35.40. According to the industry distribution chart, Carasent AB (publ) ranks #525 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 79.8%.
Is Carasent AB (publ)'s PS Ratio too high?
Carasent AB (publ)'s current PS Ratio of 4.34 is 23% below median its 10-year median of 5.65. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 35.40. The Healthcare Providers & Services industry median PS Ratio is 1.47. Carasent AB (publ)'s value of 4.34 is 196.2% above this industry median. Based on the distribution chart, Carasent AB (publ) ranks #525 out of 658 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s PS Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #525 out of 658 companies for PS Ratio. This places Carasent AB (publ) in the lower half of its industry. The industry median PS Ratio is 1.47. Carasent AB (publ)'s value of 4.34 is 196.2% above this benchmark. Historically, Carasent AB (publ)'s own PS Ratio has ranged from 0.54 to 35.40 over the past decade. While the company's 10-year median is 5.65 vs. the industry median of 1.47, Carasent AB (publ) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.47, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current PS Ratio of 4.34 is 196.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current PS Ratio is 4.34, which is 23% below median its own 10-year median of 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Based on GuruFocus' analysis, Carasent AB (publ) (FRA:E0C) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.46, compared to a current price of €2.06 — trading 16.5% below its estimated fair value. The current PS Ratio is 4.34, which is 23% below median its 10-year median of 5.65 and 196.2% above the Healthcare Providers & Services industry median of 1.47. Carasent AB (publ)'s overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Carasent AB (publ) (FRA:E0C), the current PS Ratio is 4.34 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (FRA:E0C) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of €2.06 is trading 16.5% below its estimated GF Value™ of €2.46.
GuruFocus considers Carasent AB (publ) to be Modestly Undervalued.
Key valuation signals for FRA:E0C:
PS Ratio: 4.34 (23% below median its 10-year median of 5.65)
GF Value™: €2.46 vs. price of €2.06 (16.5% below fair value)
Industry Position: 196.2% above the Healthcare Providers & Services median (#525 of 658)
No single metric tells the full story. See the FRA:E0C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
79GF Score
Get the complete analysis for FRA:E0C
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E0C has been successfully added to your 
